Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04673591
Other study ID # OG-061-01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 9, 2020
Est. completion date January 12, 2022

Study information

Verified date February 2022
Source T-Balance Therapeutics GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.


Description:

This study will consist of a screening phase, a treatment phase and a follow-up phase. Eligible subjects will undergo a bronchial allergen provocation (BAP) with mite allergen to assess the asthmatic response before and after treatment. Subjects will be randomized to two parallel treatment groups. Each subject will be treated weekly over 12 weeks either with test product or with the reference product (placebo).


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date January 12, 2022
Est. primary completion date January 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Willing and able to give written informed consent. 2. Male or female subject aged 18 to 65 years (both inclusive). 3. Established diagnosis of mild controlled allergic asthma (GINA 2019) and history of allergic bronchial asthma for at least 1 year. 4. BMI of 18.0 to 30.0 (both inclusive). 5. Non-smoker (all substances). 6. Specific IgE to HDM (Dermatophagoides farinae) = class 2 in radioallergosorbent test (RAST). 7. BHR (i.e., a decrease in FEV1 of at least 20%) measured by methacholine challenge. 8. FEV1 = 75% of predicted value (according to height, weight and sex). 9. Subject must demonstrate a significant EAR and LAR without rescue medication use within the first 7 hours after BAP. 10. No clinically relevant abnormalities in 12-lead ECG at screening. Exclusion Criteria: 1. Severe, unstable bronchial asthma. 2. Exacerbation of asthma = 4 weeks prior to screening. 3. Treatment with parenteral and oral corticosteroids 6 weeks prior to screening and during the study. 4. Treatment with inhaled corticosteroids, methylxanthines (e.g., theophyllin), anticholinergics (e.g., ipratropium bromide), leukotriene modifiers (e.g., montelukast), tiotropium bromide, cromolyn or nedocromil within 2 weeks prior to screening and during the study. 5. Current treatment with any immunosuppressants (e.g., monoclonal antibodies, methotrexate, cyclosporin). 6. Specific immunotherapy (SCIT) to mite within 3 years prior to screening. 7. Serious adverse drug reaction to previous biological treatment. 8. Previous therapy with a mAb targeting CD4, including tregalizumab. 9. Known hypersensitivity to any constituents of tregalizumab and/or other mAbs, that, in the opinion of the investigator or Medical Monitor, contraindicates participation. 10. Previous inclusion in this study. 11. Serum transaminases, ALAT and/or ASAT > 2.5-fold ULN at screening. 12. Bilirubin > 34.2 µmol/L at screening. 13. AP > 2-fold ULN at screening. 14. Urea nitrogen > 1.5-fold ULN at screening. 15. Kidney insufficiency as defined by creatinine level > 133 µmol/L at screening. 16. History of severe allergic or anaphylactic reaction to proteins of human origin (e.g. vaccination reaction, biological therapy). 17. Presence or history of malignancy within the previous 5 years (except completely resected squamous or basal cell carcinoma of the skin). 18. Presence or history of clinically significant major disease (e.g., severe heart/lung disease New York Heart Association [NYHA] Class = 3, autoimmune disease [apart from rheumatoid arthritis], acute uncontrolled hyper- or hypo-thyroidism, severe uncontrolled hypo or hypertension). 19. Serious local (e.g., abscess) or systemic (e.g., pneumonia, septicemia) infection or recurrent chronic infections within 6 weeks prior to screening visit or during the screening period. 20. Any infection requiring antibiotic therapy by any route of administration within 4 weeks prior to screening. 21. Vaccination with live, live attenuated, and/or killed vaccines in the 12 weeks prior to the first administration of the study drug and during the study. 22. Positive diagnosis for acute or chronic infections (e.g. HCV, HBV, HIV) at screening or history of previous chronic infection. 23. Acute or clinically symptomatic EBV (infectious mononucleosis) or CMV infection. 24. Presence or history of latent or active tuberculosis. 25. Known immune deficiency. 26. Presence or history of lymphoproliferative disease, including lymphoma and lymphadenopathy. 27. Presence or history of clinically significant drug or alcohol abuse. 28. Employee at study site or any institution involved in this study (including the sponsor), or spouse/partner or relative of an investigator. 29. Pregnant or nursing woman or woman considering to become pregnant during the study or in the 3 months after the last administration of study drug. 30. Woman of childbearing potential (unless surgically sterile or post-menopausal > 52 weeks) who is not using two (2) independent effective contraceptive methods (e.g., oral or injectable contraceptives, intra-uterine devices, double barrier method, contraceptive patch or female sterilization) during the study and for at least 3 months after the last administration of study drug OR Non-vasectomized man who, during the study or in the 3 months after the last administration of study drug, is not using two (2) independent effective contraceptive methods (as specified above) or is planning a sperm donation. 31. Donation of blood within 30 days prior to screening until end of study. 32. Participation in another clinical trial within 90 days before screening or during the study. 33. Inability or lacking motivation to adhere to the study requirements and to comply with the study schedule. 34. Imprisonment or placement in an institution (AMG § 40 (1), sentence 4).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tregalizumab
a monoclonal antibody designed for the treatment of allergic asthma indication
Other:
Placebo
Matched Placebo

Locations

Country Name City State
Germany Medaimun GmbH Frankfurt

Sponsors (1)

Lead Sponsor Collaborator
T-Balance Therapeutics GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline-corrected late asthmatic response measured by the area under the curve for the forced expiratory volume (FEV1) at 4 to 7 hours after bronchial allergen provocation Day 84
Secondary Change in late asthmatic response, as measured from 4 to 7 hours after bronchial allergen provocation by the maximum decrease in the normalized forced expiratory volume (FEV1) values Baseline and Day 84
Secondary Change in early asthmatic response, as measured from 0 to 3 hours after bronchial allergen provocation by the maximum decrease in the normalized forced expiratory volume (FEV1) values Baseline and Day 84
Secondary Change in early asthmatic response, as measured from 0 to 3 hours after bronchial allergen provocation by the area under the curve of the normalized forced expiratory volume (FEV1) values Baseline and Day 84
Secondary Fraction of eNO (FeNO) absolute levels and delta increase after bronchial allergen provocation Baseline and Day 84
Secondary Dose of methacholine causing a decrease in forced expiratory volume (FEV1) of at least 20% (PD20) Baseline, Day 85, Day 112
Secondary Impact of tregalizumab on TH1, TH2 and TH17 cytokines in blood Baseline, Day 1, Day 85
Secondary Impact of tregalizumab on TH1, TH2 and TH17 cytokines and T-cell transcription factors in sputum Day 1 until Day 85
Secondary Number of eosinophils, neutrophils, macrophages and lymphocytes in sputum Day 1 until Day 85
Secondary Eosinophil cationic protein (ECP) concentration in sputum Day 1 until Day 85
Secondary Number of eosinophils in blood Baseline, at Day 1, Day 84 and Day 85
Secondary Change in mite-specific IgE, IgG4, total IgE and IgG levels in blood Baseline and Day 84
Secondary Impact of tregalizumab on the expression of markers of PBMC lineage in blood Baseline until Day 112
Secondary Incidence and severity of adverse events (AEs) in the participants Approximatively 27 weeks (study duration)
Secondary Levels of specific anti-tregalizumab antibodies in blood Day 1, Day 36, Day 84
Secondary Number of rescue ß2-agonist puffs used Approximatively for 27 weeks
Secondary Change of VAS Nasal Symptom Score Baseline and Day 84
Secondary Quality of life assessed with Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12) Baseline and Day 84
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00490425 - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis